An Open Label Extension of a Study of Topiramate in Chronic Migraine.
CompletedPhase 3NCT00210873
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of headaches in adults with chronic migraine. Topiramate has been approved to prevent migraine headaches.
Study details
- Official title
- An Open-label Study of the Safety and Efficacy of Topiramate for the Prophylaxis of Chronic Migraine: Extension Study to CAPSS-276
- Conditions
- Interventions
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Collaborators
- Ortho-McNeil Neurologics, Inc.
- Start date
- 2004-02
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of chronic migraine * successfully finished double-blind portion of the CAPSS-276 study or discontinued the study after a minimum of 4 weeks maintenance treatment due to lack of effect of study drug * in generally good health * able to take medicine orally * if female, using birth control. Exclusion Criteria: * Cannot have a more painful condition than the headache pain * cannot be taking any other medications not allowed by the study protocol * no abnormal liver tests * not compliant with study medication during the CAPSS-276 study * cannot be pregnant or breast-feeding.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00210873